LU501136B1 - Method for preparing medical modified sodium hyaluronate and polycaprolactone gel - Google Patents
Method for preparing medical modified sodium hyaluronate and polycaprolactone gel Download PDFInfo
- Publication number
- LU501136B1 LU501136B1 LU501136A LU501136A LU501136B1 LU 501136 B1 LU501136 B1 LU 501136B1 LU 501136 A LU501136 A LU 501136A LU 501136 A LU501136 A LU 501136A LU 501136 B1 LU501136 B1 LU 501136B1
- Authority
- LU
- Luxembourg
- Prior art keywords
- gel
- sodium hyaluronate
- polycaprolactone
- solution
- pcl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Disclosed in the present invention is a method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel, which relates to the field of cosmetic filling materials. The method includes: preparing polycaprolactone (PCL) microspheres; mixing an alkaline solution, a cross-linking agent and 1, 4-butanediol diglycidyl ether to obtain a mixed solution; adding sodium hyaluronate dry powder into the mixed solution until the sodium hyaluronate dry powder is dissolved; adding the PCL microspheres, and carrying out stirring for normal-temperature cross-linking reaction to obtain gel; carrying out reaction on the gel at a low temperature and a high temperature separately; and carrying out dialysis, addition of a LIDCAINE solution, extrusion and screening to obtain micro gel. By wrapping the microspheres in cross-linked sodium hyaluronate gel, the present invention effectively solves a supporting problem caused by pure use of sodium hyaluronate gel and solves a layering problem of a microsphere material; moreover, the medical modified gel may have an effect of lubrication during use for injection, thereby solving a problem of a pushing force; and LIDOCAINE having a concentration of 0.3% is used, and can effectively relieve pain during injection, thereby improving comfort level of a patient during injection.
Description
[0001] The present invention relates to the field of cosmetic filling materials, and in particular to a method for preparing medical modified gel of sodium hyaluronate and polycaprolactone.
[0002] With the effects of excellent biological adaptability, easy absorption by a human body after degradation and capability to keep skin moisturized and tender, the hyaluronic acid is applied to the fields of medical treatment and cosmetology, and is mainly applied to micro-plastic surgery in the cosmetology and used for filling faces or pits. The hyaluronic acid can improve skin nutrition metabolism, make skin tender and smooth, remove wrinkles, increase elasticity and prevent aging, is a natural polysaccharide structure, and is an important basic substance for skin moisture tenderness, with strong water absorption and special water retention effect. Polycaprolactone (PCL) is a degradable material which is safe and free of toxic and side effects, and has excellent biological adaptability and degradability, thereby being a common filling material in cosmetic plastic surgery.
[0003] However, the existing filling material for cosmetic plastic surgery has the problem of layering, affecting the cosmetic effect of plastic surgery, has the problems of pain during injection, making the patient psychologically resistant and frightened, and is unsmooth during injection. Therefore, a method for preparing medical modified gel of sodium hyaluronate and polycaprolactone is designed to solve the above problems.
1
SUMMARY LU501136
[0004] The objective of the present invention is to provide a method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel in order to solve the defects in the prior art.
[0005] In order to achieve the above objective, the present invention uses the following technical solution:
[0006] the method for preparing medical modified gel of sodium hyaluronate and polycaprolactone includes:
[0007] step 1, preparing polycaprolactone (PCL) microspheres;
[0008] step 2, mixing an alkaline solution, a cross-linking agent and 1, 4-butanediol diglycidyl ether to obtain a mixed solution;
[0009] step 3, adding sodium hyaluronate dry powder into the mixed solution until the sodium hyaluronate dry powder is dissolved, adding the PCL microspheres, and carrying out stirring for normal-temperature cross-linking reaction to obtain gel;
[0010] step 4, carrying out chemical cross-linking reaction on the gel at a low temperature;
[0011] step 5, carrying out hot alkali activation reaction on the gel at a high temperature;
[0012] step 6, using a phosphate buffer saline (PBS) buffer solution to carry out swelling dialysis to obtain a gel block, adding a LIDOCAINE solution in proportion, and carrying out sealed preservation for 12 hours or above at 2°C to 10°C to completely swell and absorb the gel block, a final concentration of LIDOCAINE being 3 mg/ml;
[0013] step 7, extruding and screening the dialyzed gel block to obtain micro gel; and
[0014] step 8, putting the micro gel into a three-dimensional motion mixer for mixing to obtain the medical modified gel.
[0015] Preferably, a method for preparing the PCL microspheres includes: emulsifying a PCL solution, a hydroxy propyl methyl cellulose (HPMC) solution and a polyvinyl alcohol (PVA) solution in a shear mixing emulsifier to obtain an emulsion, 2 heating and stirring the emulsion, and then carrying out washing, screening and 7501196 collecting to obtain the PCL microspheres.
[0016] Preferably, a particle size of the PCL microsphere ranges from 10 um to 100 um.
[0017] Preferably, a particle size of the PCL microsphere ranges from 25 um to 50 um.
[0018] Preferably, the alkaline solution in step 2 is a sodium hydroxide solution having a pondus hydrogenii (PH) value greater than 11 and a concentration of 0.1% to 4%.
[0019] Preferably, a cross-linking reaction temperature ranges from 18°C to 26°C and reaction time is 3 h in step 3.
[0020] Preferably, a reaction temperature ranges from 2°C to 10°C and reaction time ranges from 12 h to 24 h in step 4; and a temperature ranges from 25°C to 65°C and reaction time ranges from 0.5 h to 2.5 h in step 5.
[0021] Preferably, a PH value of the buffer solution ranges from 6.0 to 7.5, osmotic pressure ranges from 270 mOsm/L to 350 mOsm/L, a water temperature ranges from 18°C to 26°C, use amount of the buffer solution is 500 times to 1000 times of amount of the sodium hyaluronate dry powder, and the number of times of dialysis ranges from 3 to 8 in step 6.
[0022] Preferably, the mixer has a temperature lower than 20°C for constant-speed three-dimensional shaking and slow movement lasting for 40 h to obtain the gel having a PH value of 6.8 to 7.6 in step 8.
[0023] Medical modified gel of sodium hyaluronate and polycaprolactone is prepared by the method for preparing medical modified gel of sodium hyaluronate and polycaprolactone.
[0024] The present invention has the beneficial effects:
[0025] the present invention effectively solves a supporting problem caused by pure use of sodium hyaluronate gel and solves a layering problem of a microsphere material by physically mixing sodium hyaluronate with a solution, then adding PCL microspheres for the cross-linking reaction at a normal temperature, then carrying out 3 chemical cross-linking reaction on a mixture of sodium hyaluronate and the PCL 7501136 microspheres at a low temperature, and finally carrying out hot alkali activation reaction on the mixture of sodium hyaluronate and the PCL microspheres at a high temperature to wrap the microspheres in cross-linked sodium hyaluronate gel; moreover, during use for injection, the medical modified gel may have an effect of lubrication, and solves a problem of a pushing force; and in addition, the LIDOCAINE having the concentration of 0.3% is used in the present invention, and may effectively relieve pain during injection, thereby improving comfort level of a patient during injection.
[0026] The technical solutions of the examples of the present invention will be clearly and completely described below in conjunction with the accompanying drawings of the examples of the present invention. Apparently, the examples described are merely some rather than all of the examples of the present invention.
[0027] Example 1
[0028] A polycaprolactone (PCL) solution, a hydroxy propyl methyl cellulose (HPMC) solution and a polyvinyl alcohol (PVA) solution were emulsified in a shear mixing emulsifier to obtain an emulsion, and the emulsion was heated and stirred, then washed and screened, and collected to obtain PCL microspheres having a particle size of 10 um;
[0029] 3 g of a cross-linking agent, 280 g of PCL microspheres and 120 g of sodium hyaluronate dry powder were weighed; a sodium hydroxide solution having a pondus hydrogenii (PH) value greater than 11 and a concentration of 0.1%, the cross-linking agent and 1, 4-butanediol diglycidyl ether were mixed to obtain a mixed solution; the sodium hyaluronate dry powder was added into the mixed solution until the sodium hyaluronate dry powder was dissolved; the PCL microspheres were added and stirred and react for 3 h at 18°C to obtain gel; chemical cross-linking reaction was carried out on the gel for 12 h at a low temperature of 2°C; hot alkali activation reaction was carried out on the gel for 0.5 h at a high temperature of 25°C; a phosphate buffer saline (PBS) buffer solution having a PH value of 6.0 was used for 4 swelling dialysis, osmotic pressure was 270 mOsm/L, a water temperature was 18°C, 7501196 use amount of the buffer solution was 500 times of amount of the sodium hyaluronate dry powder, the number of times of dialysis was 3, and dialysis time was 44 h to obtain a gel block, a LIDOCAINE solution having a concentration of 0.3% was added in proportion, and sealed preservation was carried out for 12 h or above at 2°C to 10°C to completely swell and absorb the gel block, and a final concentration of LIDOCAINE was 3 mg/ml; a stainless steel extrusion device was used for making the gel block pass through a filter screen having a hole diameter of 50 um under positive pressure of 0.4 MPa, so as to extrude and crush the gel block into micro gel having high viscoelasticity; and the micro gel was put into a three-dimensional motion mixer having a temperature lower than 20°C for constant-speed three-dimensional shaking and slow movement lasting for 40 h to obtain gel having a PH value of 6.8.
[0030] Example 2
[0031] A PCL solution, an HPMC solution and a PVA solution were emulsified in a shear mixing emulsifier to obtain an emulsion, and the emulsion was heated and stirred, then washed and screened, and collected to obtain PCL microspheres having a particle size of 100 um;
[0032] 3 g of a cross-linking agent, 280 g of PCL microspheres and 120 g of sodium hyaluronate dry powder were weighed; a sodium hydroxide solution having a PH value greater than 11 and a concentration of 4%, the cross-linking agent and 1, 4-butanediol diglycidyl ether were mixed to obtain a mixed solution; the sodium hyaluronate dry powder was added into the mixed solution until the sodium hyaluronate dry powder was dissolved; the PCL microspheres were added and stirred and react for 3 h at 26°C to obtain gel; chemical cross-linking reaction was carried out on the gel for 24 h at a low temperature of 10°C; hot alkali activation reaction was carried out on the gel for 2.5 h at a high temperature of 65°C; a PBS buffer solution having a PH value of 7.5 was used for swelling dialysis, osmotic pressure was 350 mOsm/L, a water temperature was 26°C, use amount of the buffer solution was 1000 times of amount of the sodium hyaluronate dry powder, the number of times of dialysis was 8, and dialysis time was 44 h to obtain a gel block, a LIDOCAINE 5 solution having a concentration of 0.3% was added in proportion, and sealed 7501196 preservation was carried out for 12 h or above at 2°C to 10°C to completely swell and absorb the gel block, and a final concentration of LIDOCAINE was 3 mg/ml; a stainless steel extrusion device was used for making the gel block pass through a filter screen having a hole diameter of 50 um under positive pressure of 0.4 MPa, so as to extrude and crush the gel block into micro gel having high viscoelasticity; and the micro gel was put into a three-dimensional motion mixer having a temperature lower than 20°C for constant-speed three-dimensional shaking and slow movement lasting for 40 h to obtain gel having a PH value of 7.6.
[0033] Example 3
[0034] A PCL solution, an HPMC solution and a PVA solution were emulsified in a shear mixing emulsifier to obtain an emulsion, and the emulsion was heated and stirred, then washed and screened, and collected to obtain PCL microspheres having a particle size of 25 um;
[0035] 3 g of a cross-linking agent, 280 g of PCL microspheres and 120 g of sodium hyaluronate dry powder were weighed; a sodium hydroxide solution having a PH value greater than 11 and a concentration of 3.5%, the cross-linking agent and 1, 4-butanediol diglycidyl ether were mixed to obtain a mixed solution; the sodium hyaluronate dry powder was added into the mixed solution until the sodium hyaluronate dry powder was dissolved; the PCL microspheres were added and stirred and react for 3 h at 18°C to obtain gel; chemical cross-linking reaction was carried out on the gel for 24 h at a low temperature of 2°C; hot alkali activation reaction was carried out on the gel for 1 h at a high temperature of 50°C; a PBS buffer solution having a PH value of 6.86 was used for swelling dialysis, osmotic pressure was 330 mOsm/L, a water temperature was 18°C, use amount of the buffer solution was 750 times of amount of the sodium hyaluronate dry powder, the number of times of dialysis was 3, and dialysis time was 44 h to obtain a gel block, a LIDOCAINE solution having a concentration of 0.3% was added in proportion, and sealed preservation was carried out for 12 h or above at 2°C to 10°C to completely swell and absorb the gel block, and a final concentration of LIDOCAINE was 3 mg/ml; a 6 stainless steel extrusion device was used for making the gel block pass through a filter 7501196 screen having a hole diameter of 50 um under positive pressure of 0.4 MPa, so as to extrude and crush the gel block into micro gel having high viscoelasticity; and the micro gel was put into a three-dimensional motion mixer having a temperature lower than 20°C for constant-speed three-dimensional shaking and slow movement lasting for 40 h to obtain gel having a PH value of 6.8.
[0036] Example 4
[0037] A PCL solution, an HPMC solution and a PVA solution were emulsified in a shear mixing emulsifier to obtain an emulsion, and the emulsion was heated and stirred, then washed and screened, and collected to obtain PCL microspheres having a particle size of 50 um;
[0038] 3 g of a cross-linking agent, 280 g of PCL microspheres and 120 g of sodium hyaluronate dry powder were weighed; a sodium hydroxide solution having a PH value greater than 11 and a concentration of 3.5%, the cross-linking agent and 1, 4-butanediol diglycidyl ether were mixed to obtain a mixed solution; the sodium hyaluronate dry powder was added into the mixed solution until the sodium hyaluronate dry powder was dissolved; the PCL microspheres were added and stirred and react for 3 h at 26°C to obtain gel; chemical cross-linking reaction was carried out on the gel for 24 h at a low temperature of 2°C; hot alkali activation reaction was carried out on the gel for 1 h at a high temperature of 50°C; a PBS buffer solution having a PH value of 6.86 was used for swelling dialysis, osmotic pressure was 330 mOsm/L, a water temperature was 26°C, use amount of the buffer solution was 750 times of amount of the sodium hyaluronate dry powder, the number of times of dialysis was 8, and dialysis time was 44 h to obtain a gel block, a LIDOCAINE solution having a concentration of 0.3% was added in proportion, and sealed preservation was carried out for 12 h or above at 2°C to 10°C to completely swell and absorb the gel block, and a final concentration of LIDOCAINE was 3 mg/ml; a stainless steel extrusion device was used for making the gel block pass through a filter screen having a hole diameter of 50 um under positive pressure of 0.4 MPa, so as to extrude and crush the gel block into micro gel having high viscoelasticity; and the 7 micro gel was put into a three-dimensional motion mixer having a temperature lower 7501136 than 20°C for constant-speed three-dimensional shaking and slow movement lasting for 40 h to obtain gel having a PH value of 7.6.
[0039] What is described above is merely preferred specific implementation of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or changes made by those skilled in the technical field according to the technical solution and the inventive concept of the present invention within the technical scope disclosed by the present invention shall fall within the scope of protection of the present invention. 8
Claims (10)
1. A method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel, comprising: step 1, preparing polycaprolactone (PCL) microspheres; step 2, mixing an alkaline solution, a cross-linking agent and 1, 4-butanediol diglycidyl ether to obtain a mixed solution; step 3, adding sodium hyaluronate dry powder into the mixed solution until the sodium hyaluronate dry powder is dissolved, adding the PCL microspheres, and carrying out stirring for normal-temperature cross-linking reaction to obtain gel; step 4, carrying out chemical cross-linking reaction on the gel at a low temperature; step 5, carrying out hot alkali activation reaction on the gel at a high temperature; step 6, using a phosphate buffer saline (PBS) buffer solution to carry out swelling dialysis to obtain a gel block, adding a LIDOCAINE solution in proportion, and carrying out sealed preservation for 12 hours or above at 2°C to 10°C to completely swell and absorb the gel block, a final concentration of LIDOCAINE being 3 mg/ml; step 7, extruding and screening the dialyzed gel block to obtain micro gel; and step 8, putting the micro gel into a three-dimensional motion mixer for mixing to obtain the medical modified gel.
2. The method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel according to claim 1, wherein a method for preparing the PCL microspheres comprises: emulsifying a PCL solution, a hydroxy propyl methyl cellulose (HPMC) solution and a polyvinyl alcohol (PVA) solution in a shear mixing emulsifier to obtain an emulsion, heating and stirring the emulsion, and then carrying out washing, screening and collecting to obtain the PCL microspheres.
3. The method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel according to claim 1, wherein a particle size of the PCL microsphere ranges from 10 um to 100 um.
4. The method for preparing medical modified gel of sodium hyaluronate and 9 polycaprolactone gel according to claim 1, wherein a particle size of the PCL microsphere ranges from 25 um to 50 um.
5. The method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel according to claim 1, wherein the alkaline solution in step 2 is a sodium hydroxide solution having a pondus hydrogenii (PH) value greater than 11 and a concentration of 0.1% to 4%, and the LIDOCAINE added in step 6 has a concentration of
0.3%.
6. The method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel according to claim 1, wherein a cross-linking reaction temperature ranges from 18°C to 26°C and reaction time is 3 h in step 3.
7. The method for preparing medical modified gel of sodium hyaluronate and polycaprolactone according to claim 1, wherein a reaction temperature ranges from 2°C to 10°C and reaction time ranges from 12 h to 24 h in step 4; and a temperature ranges from 25°C to 65°C and reaction time ranges from 0.5 h to 2.5 h in step 5.
8. The method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel according to claim 1, wherein a PH value of the buffer solution ranges from 6.0 to 7.5, osmotic pressure ranges from 270 mOsm/L to 350 mOsm/L, a water temperature ranges from 18°C to 26°C, use amount of the buffer solution is 500 times to 1000 times of amount of the sodium hyaluronate dry powder, and the number of times of dialysis ranges from 3 to 8 in step 6.
9. The method for preparing medical modified gel of sodium hyaluronate and polycaprolactone gel according to claim 1, wherein the mixer has a temperature lower than 20°C for constant-speed three-dimensional shaking and slow movement lasting for 40 h to obtain the gel having a PH value of 6.8 to 7.6 in step 8.
10. Medical modified gel of sodium hyaluronate and polycaprolactone gel, prepared by the method for preparing medical modified gel of sodium hyaluronate and polycaprolactone according to any one of claims 1 to 9.
10
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU501136A LU501136B1 (en) | 2021-12-31 | 2021-12-31 | Method for preparing medical modified sodium hyaluronate and polycaprolactone gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU501136A LU501136B1 (en) | 2021-12-31 | 2021-12-31 | Method for preparing medical modified sodium hyaluronate and polycaprolactone gel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU501136B1 true LU501136B1 (en) | 2022-06-30 |
Family
ID=82272157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU501136A LU501136B1 (en) | 2021-12-31 | 2021-12-31 | Method for preparing medical modified sodium hyaluronate and polycaprolactone gel |
Country Status (1)
| Country | Link |
|---|---|
| LU (1) | LU501136B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531607A (en) * | 2022-10-21 | 2022-12-30 | 北京安奇生物医药科技有限公司 | Preparation method of mixed degradable material microsphere and composite preparation |
-
2021
- 2021-12-31 LU LU501136A patent/LU501136B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531607A (en) * | 2022-10-21 | 2022-12-30 | 北京安奇生物医药科技有限公司 | Preparation method of mixed degradable material microsphere and composite preparation |
| CN115531607B (en) * | 2022-10-21 | 2023-08-22 | 北京安奇生物医药科技有限公司 | Preparation method of mixed degradable material microsphere and compound preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2861626B1 (en) | Method of preparing a composition based on hyaluronic acid | |
| Kumar | A review of chitin and chitosan applications | |
| JP3337472B2 (en) | Wound healing agent | |
| CN108853570B (en) | Hemostatic sponge and preparation method thereof | |
| Sabbagh et al. | Strategies in improving properties of cellulose-based hydrogels for smart applications | |
| CN101036808B (en) | Cross-linked hyaluronic acid derivatives preparation and the preparing technique | |
| CN101264348A (en) | Preparation technique of sodium hyaluronate gel granule | |
| CN102911380A (en) | Hyaluronan and biodegradable high polymer modified material and preparation method | |
| CN111249189B (en) | An injectable facial filler composition for skin care and plastic, and its preparation method | |
| WO1997004012A1 (en) | Polysaccharide gel composition | |
| EP2155810A2 (en) | Alginate coated, polysaccharide gel-containing foam composite, preparative methods, and uses thereof | |
| JPH0430961B2 (en) | ||
| CN113087935B (en) | Composite sodium hyaluronate gel for resisting hyaluronidase hydrolysis and preparation method thereof | |
| CN113476663A (en) | Preparation method of medical modified sodium hyaluronate polyhexamethylene lactone gel | |
| EP2570141A2 (en) | Dermal filler composition | |
| CN107522881B (en) | Method for preparing single-phase modified sodium hyaluronate gel | |
| CN102558600A (en) | Cross-linked hyaluronan sponge and preparation method for same | |
| LU501136B1 (en) | Method for preparing medical modified sodium hyaluronate and polycaprolactone gel | |
| CN104693476B (en) | A kind of biodegradable medical sthptic sponge and preparation method thereof | |
| Al-Sibani et al. | Effect of hyaluronic acid initial concentration on cross-linking efficiency of hyaluronic acid–based hydrogels used in biomedical and cosmetic applications | |
| CN105920659A (en) | Bacteriostatic hydrogel dressing for wound repair and preparation method thereof | |
| CN109498833A (en) | A kind of Medical absorbable polysaccharide composite material and application thereof | |
| CN114931666B (en) | Preparation method of hyaluronic acid-collagen composite crosslinked microsphere for facial filling | |
| CN104761735B (en) | A kind of preparation method with the cross-linking sodium hyaluronate gel for suppressing hyaluronidase activity | |
| CN103550815A (en) | Preparation method of microporous polysaccharide microspheres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Effective date: 20220630 |